Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The drug reduces the life span of cells harboring latent virus and blocks inflammation that allows the reservoir to persist.
Ruxolitinib might have contributed to a functional cure after a stem cell transplant without a rare mutation.
Two Campbell Foundation grantees hope to find out and better understand the HIV reservoir. Their work could help research for a cure.
One person treated with a broadly neutralizing antibody plus romidepsin remained in remission for 3.7 years.
The National Institutes of Health awarded grants for HIV cure research to these 10 organizations. One focuses on pediatric populations.
With $600,000 in amfAR HIV grants, research teams explore CAR-T cells, bFAbs and CRISPR/Cas9 gene editing to eradicate the reservoir.
Any HIV cure on the horizon will have to tackle macrophage immune cells as well as CD4 T Cells, a study indicates.
One avenue in the HIV cure research field involves using agents that prevent reactivation of HIV replication in latently infected cells.
In a study of people with a low but detectable viral load despite adherence to treatment, infected cells were apparently cloning themselves.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
As a result, cure treatments may have to approach these two targets differently.
Such latently infected cells remain under the radar of antiretroviral treatment, which only works on replicating cells.
A recent study found that agents used to wake up resting HIV-infected cells probably work only on 5 percent of such cells.
Researchers say CD32 is not a biomarker for immune cells latently infected with HIV but one for actively infected cells.
Gilead Sciences’ second round of cure grants supports these five research projects.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.